EP1438320A1 - Novel hydroxyalkyl indolocarbazole derivatives, preparation method and pharmaceutical compositions containing same - Google Patents
Novel hydroxyalkyl indolocarbazole derivatives, preparation method and pharmaceutical compositions containing sameInfo
- Publication number
- EP1438320A1 EP1438320A1 EP02796813A EP02796813A EP1438320A1 EP 1438320 A1 EP1438320 A1 EP 1438320A1 EP 02796813 A EP02796813 A EP 02796813A EP 02796813 A EP02796813 A EP 02796813A EP 1438320 A1 EP1438320 A1 EP 1438320A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- formula
- compound
- linear
- branched
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
Definitions
- the present invention relates to new derivatives of hydroxyalkyl indolocarbazole, their process of preparation and the pharmaceutical compositions which contain them.
- the compounds of the present invention constitute derivatives of rebeccamycin, this product having an inhibitory activity of topoisomerase I making it particularly useful in the treatment of tumors.
- Many chemical modifications of rebeccamycin have been made, both in terms of the functional groups present on the molecule (WO 98/07433) and their positions on the hexacyclic skeleton (WO 98/07433) and their positions on the hexacyclic skeleton (WO
- the compounds described by the Applicant surprisingly exhibit selective inhibitory activity on a kinase family and more specifically on the kinase GSK-3 (glycogen synthase kinase).
- Glycogen Synthase Kinase 3 is found in most human tissues
- GSK-3 (muscle, liver, pancreas, heart, intestine, ). This enzyme is involved in the insulin signaling pathway. Insulin via the PI 3-kinase pathway inhibits GSK-3, leading to an increase in the synthesis of glycogen stores. GSK-3 also phosphorylates the insulin substrate proteins resulting in desensitization of the insulin stimulation pathways. Experiments carried out in the Zucker rat (obese and diabetic) have shown that inhibition of GSK-3 leads to stimulation of glucose transport. It was also found that the activity of GSK-3 was increased in models or in pathological situations in animals as in humans (type II diabetes).
- GSK-3 activity makes it possible to prevent neuronal death in subjects suffering from neurodegenerative pathologies, as well as to prevent the death of healthy cells in a subject suffering from affection. tumor and treat with cytotoxic agents.
- the compounds capable of inhibiting the synthesis of GSK-3 are therefore particularly useful for the treatment of type II diabetes, obesity, pathologies of the central nervous system, Alzheimer's disease, Parkinson's disease , and to prevent normal cell apoptosis induced by anticancer drugs.
- the compounds described by the Applicant in addition to the fact that they are new, unexpectedly exhibit selective inhibitory activity with respect to the Glycogen Synthase Kinase 3, making them particularly useful for their use as a medicament, in the treatment of the pathologies mentioned above.
- Ri and R 2 identical or different, independently of each other, each represent a group chosen from hydrogen, alkyl (C ⁇ _-C 6 ) linear or branched, arylalkyl
- C ⁇ -C 6 linear or branched, hydroxy, hydroxyalkyl (C ⁇ -C 6 ) linear or branched, dihydroxyalkyl (C ⁇ -C 6 ) linear or branched, alkoxy (C ⁇ -C 6 ) linear or branched, alkoxy (C ⁇ -C 6) alkyl (C ⁇ -C6) linear or branched, amino, and aminoalkyl (C ⁇ -C6) linear or branched, the amino moiety in each of the groups being optionally substituted by one or two identical or different, selected from alkyl
- Ra and Rb identical or different, independently of each other, each represent a linear or branched alkylene chain (C ⁇ -C 6 ), • Xi, X 2 and X 3) identical or different, independently of each other, each represent a group chosen from hydroxy, alkoxy (C ⁇ -C 6 ) linear or branched, aryloxy, arylalkoxy (C ⁇ -C 6 ) linear or branched, alkyl (C ⁇ ⁇ C 6 ) linear or branched, amino (optionally substituted by one or two groups, identical or different, alkyl (C ⁇ -C 6 ) linear or branched), halogen, alkylcarbonyloxy (C ⁇ -C 6 ) linear or branched, and azido,
- aryl group is understood a phenyl or naphthyl group, and by isomers one understands the optical isomers (racemates, enantiomers and diastereoisomers).
- hydrochloric hydrobromic, sulfuric, phosphonic, acetic, trifluoroacetic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, tartaric, maleic, citric, ascorbic, oxalic, methane acids. sulfonic, camphoric, etc.
- Preferred Ri groups of the compounds of the invention are the hydrogen atom, the alkyl group (C ⁇ -C6) linear or branched alkyl or hydroxy (C ⁇ -C6) linear or branched.
- the preferred group R 2 of the compounds of the invention is the hydrogen atom.
- the preferred compounds are the compounds of formula (I) in which Ra and Rb, identical, represent a linear alkylene chain (C ⁇ -C).
- the groups X_. X and X 3 preferred, compounds of the invention are chosen from hydroxy, alkoxy (C ⁇ -C 6 ) linear or branched and alkylcarbonyloxy (C ⁇ -C 6 ) linear or branched.
- Preferred groups X 4 are selected from -R c-Xi groups in which Rc represents a methylene and X group. represents a group chosen from hydroxy, halogen, alkoxy (C ⁇ -C 6 ) linear or branched and alkylcarbonyloxy (C _ -C 6 ).
- the preferred compounds are the compounds of formula (LA):
- R_, R 2 , Ra, Rb, Xi, X, X 3 and X 4 are as defined in formula (I).
- the preferred compound of the invention is 3,9-bis (hydroxymethyl) -12- (4-O-methyl- ⁇ -D- glucopyranosyl) -12,13-dihydro-5H-indolo [2,3- ⁇ ] pyrrolo [3,4-c] carbazole-5,7 (6H) -dione
- the isomers as well as the addition salts with a pharmaceutically acceptable acid or base of the preferred compounds form an integral part of the invention.
- the present invention also relates to the process for preparing the compounds of formula (I), characterized in that a compound of formula (II) is used as starting material:
- the compounds of formula (II), (IV), and (VIII) are either commercial compounds, or obtained according to conventional methods of organic synthesis easily accessible to those skilled in the art.
- the compounds of formula (I) have a completely surprising selective inhibitory activity GSK-3 (glycogen Synthase Kinase-3). This characteristic property allows their use in the treatment of type II diabetes, obesity, pathologies of the central nervous system, Alzheimer's disease, Parkinson's disease, and for apoptosis.
- the present invention also relates to pharmaceutical compositions containing as active principle at least one compound of formula (I), one of its isomers, or one of its addition salts with a pharmaceutically acceptable acid or base, alone or in combination with one or more inert, non-toxic, pharmaceutically acceptable excipients or vehicles.
- compositions according to the invention particular mention will be made of those which are suitable for oral, parenteral (intravenous, intramuscular, or subcutaneous), per or transcutaneous, intravaginal, rectal, nasal, perlingual, buccal administration. , ocular or respiratory.
- compositions according to the invention for parenteral injections include in particular aqueous and non-aqueous sterile solutions, dispersions, suspensions or emulsions as well as sterile powders for the reconstitution of injectable solutions or dispersions.
- compositions according to the invention for solid oral administrations, include in particular simple or coated tablets, sublingual tablets, sachets, capsules, granules, and for oral, nasal, buccal or ocular administrations, include in particular emulsions, solutions, suspensions, drops, syrups and aerosols.
- compositions for rectal or vaginal administration are preferably suppositories, and those for per or trans-cutaneous administration include in particular powders, aerosols, creams, ointments, gels and patches.
- compositions cited above illustrate the invention but do not limit it in any way.
- inert, non-toxic, pharmaceutically acceptable excipients or vehicles mention may be made, by way of indication and without limitation, of diluents, solvents, preservatives, wetting agents, emulsifiers, dispersing agents, binders, swelling agents, disintegrants, retardants, lubricants, absorbents, suspending agents, colorants, flavorings, etc ...
- the useful dosage varies according to the age and weight of the patient, the route of administration, the pharmaceutical composition used, the nature and severity of the condition, and the taking of any associated treatments. The dosage ranges from 0.5 mg to 500 mg in one or more doses per day.
- the starting materials used are known products or prepared according to known procedures. The different stages of preparation lead to synthesis intermediates useful for the preparation of the compounds of the invention.
- Example 1 3,9-bis (hy roxymethyl) -l 2- (4-0-methyl- ⁇ -D-glucopyranosy ⁇ ) -l 2,13- dihydro-5i ⁇ -in (Iolo [2,3-] pyrro ⁇ o [3,4-cJcarbazole-5,7 (6H) -diione,
- Stage A 12- (2 5 3,6-tri-0-acetyl-4-f9-methyl- ⁇ -D-glucopyranosyl) -12,13-dihydro-5H- indolo [2,3-fllpyrrolo [3,4 c] carbazole-5,7 (6ii) -dione,
- Stage C 3,9-DîformyI-12- (4-t -methyl- ⁇ -D-glucopyranosyl) -12,13-dihydro-5Er- indolo [2,3- ⁇ ] pyrrolo [3,4-clcarbazole-5 , 7 (6jfif) -dione.
- stage B The compound obtained in stage B is dissolved in 13 ml of methanol, then 6 ml of a 30% aqueous solution of NH 4 OH are added. After 24 hours of stirring at room temperature, the reaction medium is evaporated to dryness. The residue is dissolved in an ethyl acetate / tetrahydrofuran mixture, acidified with an IN solution of hydrochloric acid and then extracted with ethyl acetate. The organic phase is dried over magnesium sulfate and evaporated under reduced pressure. Chromatography on silica gel of the residue (cyclohexane / acetone: 20/80) allows the expected product to be isolated. Melting point:> 300 ° C
- Stage D 3,9-bis (hydroxymethyl) -12- (4-0-methyl- ⁇ -D-glycopranosyl) -12,13- dihydro-5i-indolo [2,3- ⁇ ] pyrrolo [3,4- c] carbazoIe-5-7 (6E -dione.
- Example 2 3,9-bis (hydroxymethyl) -6-methyl-I2- (4-0-methyl- ⁇ -D- glucopyranosyl) -12,13-dihydro-5i ⁇ -mdolo [2,3-] pyrrolo [3 , 4-c] carbazole-5,7-dione.
- Stage A 12- (4-0-methyl- ⁇ -D-glucopyranosyl) -12,13-dihydrofuro [3,4-cl indolo [2,3-fl] carbazole-5,7 »dione.
- Stage B 6-methyl U2- (4-0-hy hyI- ⁇ -D-glueopyra ⁇ osyI) -12,13-dihydro-5H- mdolo [2,3 - «] pyrrolo [3,4-c] carbazole-5, 7-dione.
- Stage C 3-9-bis (hydroxymethyl) -6-methyl-12- (4-? -Methyl- ⁇ -D-glucopyranosyl) - 12-13-dihydro-5i ⁇ -indolo [2-3- ⁇ ] pyrroIo [ 3,4-c] carbazole-5,7-dio ⁇ e.
- Example 3 6- (2-hydroxyethyl) -3,9-bis (hydroxymethyl) -12- (4- "9-methyl- ⁇ -D- glucopyranosyl) -1,213-dihy dro-5H-indolo [2 , 3 - "] pyrrolo [3,4-c] carbazole-5,7-dione.
- Stage A 6- (2-hydroxyethyl) -12- (4- * -methyl- ⁇ -D-glucopyranosyl) -12,13-dihydro- 5iî-mdoIo [2,3- ⁇ ] pyrroIo [3,4-c ] earbazole-5,7-diQne.
- Stage B 6- (2-hydroxyethyl) -3,9-bis (hydroxymethyl) -12- (4- ⁇ 9-methyl- ⁇ -D- glucopyranosyl) -12,13-dihydro-5 J ff-mdoloP, 3- ⁇ ] pyrroIo [3,4-c] carbazole-5,7-dione.
- the product is obtained according to the method of Example 1, from stages A to D, using the compound obtained in preceding stage A as a substrate.
- Example 4 6-diethylaminoethyl-3,9-bis (hydroxymethyl) -12- (4- "-methyl- ⁇ -D- glucopyranosyl) -12,13-dihydro-5H-mdolol2,3- ⁇ ] pyrrolo [3, 4-c] earbazole-5,7-dione.
- Stage A 6-diethylammoethyl-12- (4-0-methyl- ⁇ -D-glucopyranosyl) -12,13-dîhydro- 5i ⁇ -indolo [2,3- ⁇ ] pyrroIo [3,4-c] carbazole-5 , 7-dione.
- Stage B 6-diethylaminoethyl-3,9-bis (hydroxymethyl) -12- (4-0-methyl- ⁇ -D- glucopyranosyl) -12, I3-dihydro-5H-indolo [2,3- ⁇ ] pyrrolo [ 3,4-c] carbazol
- the product is obtained according to the method of Example 1, from stages A to D, using the compound obtained in preceding stage A as a substrate.
- the product is obtained according to the method of stage D of example 1, using as compound the compound obtained in stage B of example 1.
- Example 6 3,9-bîs (hydroxymethyl) -12- (6-chloro-6-deoxy-4-0-methyl-I- ⁇ -D ⁇ glucopyranosyl) -12,13-dib.ydro-5H- whatsoeverolo [2, 3- ⁇ t] pyrrolo [3,4-c] carbazole-5,7 (6H) -diotte.
- Stage A 12- (6-chloro-6-deoxy-4-0-methyl- ⁇ -D-glucopyranosyl) -12,13-dihydro-5jH r - itt QloP î S- ⁇ lpyrrolop ⁇ - lcarbazole-S CôE -d ⁇ Otte.
- the product is obtained according to the method of Example 1, from stages A to D, using the compound obtained in preceding stage A as a substrate.
- Glycogen synthase kinase 3 was purified from Sf9 cells transfected as described in Eur. J. Biochem., 1992, 305-311.
- Example 1 has an IC 50 of 0.03 ⁇ M. It is therefore active vis-à-vis GSK-3 and this activity is selective as evidenced by the results set out in Examples 8 and 9 described below.
- the enzyme was purified from a homogenate of starfish oocytes (Marthasterias glacialis) in M phase as described in Ewr. J. Biochem, 1997, 243. 527-536 and J Biol.
- the IC 50 values are estimated from the dose-response curves. During this test, the compound of Example 1 has an IC 50 greater than 5 ⁇ M, thus demonstrating its weak capacity to inhibit this cyclin dependent protein kinase.
- CDK5 was expressed in E. coli as a GST (Glutathione-S-transferase) fusion protein and purified on a glutathione-agarose affinity column. CDK5 is then activated by p25 (1/1 mixture), prepared in the same way. The enzymatic activity of the CDK5 / p25 complex is measured as described above for CDK1 / cyclin B. The IC 50 values are estimated from the dose-response curves.
- Example 1 has an IC 5 o greater than 5 ⁇ M, thus demonstrating its weak ability to inhibit this cyclin dependent protein kinase.
- Example 10 Pharmaceutical composition for 1000 tablets dosed at 10 mg
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0113576A FR2831169B1 (en) | 2001-10-22 | 2001-10-22 | NOVEL INDOLOCARBAZOLE HYDROXYALKYL DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
FR0113576 | 2001-10-22 | ||
PCT/FR2002/003592 WO2003035663A1 (en) | 2001-10-22 | 2002-10-21 | Novel hydroxyalkyl indolocarbazole derivatives, preparation method and pharmaceutical compositions containing same |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1438320A1 true EP1438320A1 (en) | 2004-07-21 |
Family
ID=8868539
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02796813A Withdrawn EP1438320A1 (en) | 2001-10-22 | 2002-10-21 | Novel hydroxyalkyl indolocarbazole derivatives, preparation method and pharmaceutical compositions containing same |
Country Status (18)
Country | Link |
---|---|
US (1) | US20040242508A1 (en) |
EP (1) | EP1438320A1 (en) |
JP (1) | JP2005509641A (en) |
KR (1) | KR100588222B1 (en) |
CN (1) | CN1253463C (en) |
AR (1) | AR036898A1 (en) |
BR (1) | BR0213403A (en) |
CA (1) | CA2463923A1 (en) |
EA (1) | EA006201B1 (en) |
FR (1) | FR2831169B1 (en) |
HK (1) | HK1072774A1 (en) |
HU (1) | HUP0401885A2 (en) |
MX (1) | MXPA04003741A (en) |
NO (1) | NO20041761L (en) |
NZ (1) | NZ532365A (en) |
PL (1) | PL368237A1 (en) |
WO (1) | WO2003035663A1 (en) |
ZA (1) | ZA200402626B (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
TWI499414B (en) | 2006-09-29 | 2015-09-11 | Lexicon Pharmaceuticals Inc | Inhibitors of sodium glucose co-transporter 2 and methods of their use |
WO2008109591A1 (en) * | 2007-03-08 | 2008-09-12 | Lexicon Pharmaceuticals, Inc. | Phlorizin analogs as inhibitors of sodium glucose co-transporter 2 |
WO2012027331A1 (en) | 2010-08-27 | 2012-03-01 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
US10011637B2 (en) | 2013-06-05 | 2018-07-03 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
CN104031052B (en) * | 2014-05-20 | 2016-06-08 | 中国科学院南海海洋研究所 | Antibiotic Indimicins A E and preparation method thereof and the application in preparing antitumor drug |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000064917A2 (en) * | 1999-04-26 | 2000-11-02 | Advanced Life Sciences Inc. | Synthetic indolocarbazole regioisomers and uses thereof |
WO2004083228A1 (en) * | 1999-09-10 | 2004-09-30 | Katsuhisa Kojiri | Indolopyrrolocarbazole derivatives and antitumor agents |
FR2801054B1 (en) * | 1999-11-17 | 2003-06-13 | Adir | NOVEL DERIVATIVES OF 12,13- (PYRANOSYL) -INDOLO [2,3-A] PYRROLO [3,4-C] CARBAZOLE AND 12,13- (PYRANOSYL) -FURO [3,4-C] INDOLO [2,3 -A] CARBAZOLE, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
-
2001
- 2001-10-22 FR FR0113576A patent/FR2831169B1/en not_active Expired - Fee Related
-
2002
- 2002-10-21 CN CNB02820784XA patent/CN1253463C/en not_active Expired - Fee Related
- 2002-10-21 HU HU0401885A patent/HUP0401885A2/en unknown
- 2002-10-21 AR ARP020103953A patent/AR036898A1/en unknown
- 2002-10-21 MX MXPA04003741A patent/MXPA04003741A/en not_active Application Discontinuation
- 2002-10-21 KR KR1020047005995A patent/KR100588222B1/en not_active IP Right Cessation
- 2002-10-21 JP JP2003538176A patent/JP2005509641A/en not_active Ceased
- 2002-10-21 WO PCT/FR2002/003592 patent/WO2003035663A1/en not_active Application Discontinuation
- 2002-10-21 NZ NZ532365A patent/NZ532365A/en unknown
- 2002-10-21 PL PL02368237A patent/PL368237A1/en not_active Application Discontinuation
- 2002-10-21 BR BR0213403-9A patent/BR0213403A/en not_active IP Right Cessation
- 2002-10-21 EA EA200400533A patent/EA006201B1/en unknown
- 2002-10-21 CA CA002463923A patent/CA2463923A1/en not_active Abandoned
- 2002-10-21 EP EP02796813A patent/EP1438320A1/en not_active Withdrawn
- 2002-10-21 US US10/492,876 patent/US20040242508A1/en not_active Abandoned
-
2004
- 2004-04-02 ZA ZA2004/02626A patent/ZA200402626B/en unknown
- 2004-04-29 NO NO20041761A patent/NO20041761L/en not_active Application Discontinuation
-
2005
- 2005-04-07 HK HK05102890A patent/HK1072774A1/en not_active IP Right Cessation
Non-Patent Citations (1)
Title |
---|
See references of WO03035663A1 * |
Also Published As
Publication number | Publication date |
---|---|
NZ532365A (en) | 2005-07-29 |
CA2463923A1 (en) | 2003-05-01 |
EA200400533A1 (en) | 2004-08-26 |
HK1072774A1 (en) | 2005-09-09 |
JP2005509641A (en) | 2005-04-14 |
FR2831169B1 (en) | 2003-12-12 |
FR2831169A1 (en) | 2003-04-25 |
WO2003035663A1 (en) | 2003-05-01 |
AR036898A1 (en) | 2004-10-13 |
KR20040054735A (en) | 2004-06-25 |
MXPA04003741A (en) | 2004-07-23 |
HUP0401885A2 (en) | 2004-12-28 |
ZA200402626B (en) | 2005-06-29 |
PL368237A1 (en) | 2005-03-21 |
KR100588222B1 (en) | 2006-06-12 |
CN1253463C (en) | 2006-04-26 |
US20040242508A1 (en) | 2004-12-02 |
CN1571793A (en) | 2005-01-26 |
NO20041761L (en) | 2004-04-29 |
BR0213403A (en) | 2004-11-03 |
EA006201B1 (en) | 2005-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2406263B1 (en) | Pyrazolo[1,5-a]-1,3,5-triazine derivatives, preparation thereof, and therapeutic use thereof | |
HUT67496A (en) | Methylen-oxindole derivatives, their preparation and pharmaceutical compositions compsiring them | |
EP0839149B9 (en) | Galanthamine derivatives, preparation method therefor, use thereof as drugs, and pharmaceutical compositions containing such derivatives | |
EP1558612B1 (en) | Imidazopyridine derivatives, preparation method and pharmaceutical compositions containing same | |
CH633796A5 (en) | THERAPEUTICALLY ACTIVE DIPYRIDOINDOLES. | |
CA2436958A1 (en) | Pyrimidine acyclonucleoside derivatives, preparation method and use thereof | |
WO2003002563A1 (en) | Pyrido-pyrido-pyrrolo pyrrolo-indole and pyrido-pyrrolo pyrrolo carbazole derivatives, method for the production thereof and pharmaceutical compositions containing said derivatives | |
EP1101770B1 (en) | Derivatives of 12,13-(pyranosyl)-indolo(2,3-a)pyrrolo(3,4-c)carbazole and 12,13-(pyranosyl)-furo(3,4-c)indolo(2,3-a)carbazole, their process of preparation and pharmaceutical compositions containing them | |
EP1438320A1 (en) | Novel hydroxyalkyl indolocarbazole derivatives, preparation method and pharmaceutical compositions containing same | |
EP0117959B1 (en) | Nitrosourea derivatives, process for their preparation and pharmaceutical compositions containing them | |
EP0318392B1 (en) | N-(vinblastinoyl-23)derivatives of 1-amino methylphosphonic acids, processes for their preparation and pharmaceutical compositions containing them | |
FR2845996A1 (en) | NOVEL [3,4-A: 3,4-C] CARBAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
CA2896209A1 (en) | 3,5-diarylazaindoles as dyrk1a protein inhibitors for the treatment of cognitive deficiences associated with down's syndrome and with alzheimer's disease | |
EP0699679A1 (en) | Tetrahydropyranyl compounds, process for their preparation and pharmaceutical compositions containing them | |
FR2701261A1 (en) | New glucuronide compounds of diosmetin, process for their preparation and the pharmaceutical compositions containing them | |
EP0412015B1 (en) | Derivatives N-(vincristinyl-23) and N-(noranhydro-5-vinblastinyl-23) of amino-1 methylphosphonic acid, their process of preparation and pharmaceutical compositions containing them | |
CA1204770A (en) | Fluorinated diaminoalkene derivatives | |
FR2758562A1 (en) | NOVEL MIXED AMINOBENZYLIC ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
CH609056A5 (en) | Process for the preparation of pyrimidines | |
FR2781482A1 (en) | New 8H-thieno(2,3-b)pyrrolizin-8-one derivatives useful as anticancer agents, especially for treating solid tumors | |
CA2033798A1 (en) | Thymidine derivatives; process for preparing the same and compositions containing them | |
WO1986007057A1 (en) | Methyl derivatives of methylated bis 7h pyridocarbazoles and farmaceutical compositions containing them | |
FR2902792A1 (en) | New tetrahydro-7H-pyrano-(2,3-c)-acridin-7-one cinnamate derivatives, are specific cell cycle blockers useful as anticancer medicaments |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20040414 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: BIZOT-ESPIARD, JEAN-GUY Inventor name: RENARD, PIERRE Inventor name: PFEIFFER, BRUNO Inventor name: PIERRE, ALAIN Inventor name: HICKMAN, JOHN Inventor name: MOREAU, PASCALE Inventor name: MARMINON, CHRISTELLE Inventor name: PRUDHOMME, MICHELLE |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20061104 |